Asbestos-Related Disease. Screening and Diagnosis.

Advances in Clinical Chemistry

Volumn 57, Issue , 2012, Pages 163-185

  Rodríguez Portal, JoséAntonio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Asbestos; Computed tomography; Malignant pleural mesothelioma; Osteopontin; Soluble mesothelin

Indexed keywords

EID: 84858851390     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394384-2.00006-1     Document Type: Chapter

References (77)

1. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005, 49(Suppl. 1):S3-S8.
2. Wagner J.C., Sieggs C.A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in North Western Cape Province. Br. J. Ind. Med 1960, 17:250-271.
3. Tarrés J., Abós-Herràndiz R., Albertí C., Martínez-Artés X., Rosell-Murphy M., García-Allas I., et al. Asbestos-related diseases in a population near a fibrous cement factory. Arch. Bronconeumol. 2009, 45(9):429-434.
4. National Academy of Sciences Asbestifors Fibers: Non occupational Health Risks 1984, National Academies Press, Washington, DC.
5. Mossman B.T., Bignon J., Corn M., et al. Scientific developments and implications for public policy. Science 1990, 247:294-301.
6. Pass H.I., Carbone M. Current status of screening for malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg 2009, 21:97-104.
7. Tan E., Warren N., Darnton A.J., Hodgson J.T. Projection of mesothelioma mortality in Britain using Bayesian methods. Br. J. Cancer 2010, 103(3):430-436.
8. Sterman D.H., Albelda S.M. Advances in the diagnosis, evaluation and management of malignant pleural mesothelioma. Respirology 2005, 10:266-283.
9. Gaafar R.M., Eldin N.H. Epidemic of mesothelioma in Egypt. Lung Cancer 2005, 49(Suppl. 1):S17-S20.
10. Weder W., Opitz I., Stahel R. Multimodality strategies in malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 2009, 21(2):172-176.
11. Borczuk A.C., Cappellini C.G., Kim H.K., et al. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 2007, 26:610-617.
12. Harries P.G., Mackenzie F.A., Sheers G., et al. Radiological survey of men exposed to asbestos in naval dockyards. Br. J. Ind. Med. 1972, 29:274-279.
13. Tiitola M., Kivisaari L., Huuskonen M.S., et al. Computed tomography screening for lung cancer in asbestos-exposed workers. Lung Cancer 2002, 35:17-22.
14. Fasola G., Belvedere O., Aita M., et al. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial-an Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist 2007, 12:1215-1224.
15. Mastrangelo G., Ballarin M.N., Bellini E., Eder M., Zannol F., Gioffré F., et al. Feasibility of a screening programme for lung cancer among workers previously heavily exposed to asbestos. Med. Lav. 2009, 100(Suppl. 1):29-32.
16. Robinson M., Wiggins J. Statement on MM in the UK. Thorax 2002, 57:187.
17. Sherpereel A., Astoul P., Berghmans T., et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur. Respir. J. 2010, 35:479-495.
18. Scherpereel A., Lee Y.C.G. Biomarkers for mesothelioma. Curr. Opin. Pulm. Med. 2007, 13:339-343.
19. Chiu B., Churg A., Tengblad A., Pearce R., McCaughey W.T. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer 1984, 54(10):2195-2199.
20. Furham C., Duche J.C., Chouaid C., et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin. Biochem. 2000, 33(5):405-410.
21. Frebourg T., Lerebours G., Delpech B., et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 1987, 59(12):2104-2107.
22. Soderblom T., Pettersson T., Nyberg P., et al. High pleural fluid hyaluronan concentrations in rheumatoid arthritis. Eur. Respir. J. 1999, 13(3):519-522.
23. Welker L., Muller M., Holz O., et al. Cytological diagnosis of malignant mesothelioma-improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007, 450(4):455-461.
24. Atagi S., Ogawara M., Kawahara M., et al. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn. J. Clin. Oncol. 1997, 27(5):293-297.
25. Hedman M., Arnberg H., Wernlund J., et al. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 2003, 23:531-536.
26. Kebapci M., Vardareli E., Adapinar B., et al. CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur. Radiol. 2003, 13:2620-2626.
27. Creaney J., van Bruggen I., Hof M., Segal A., Musk A.W., de Klerk N., et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007, 132:1239-1246.
28. Goldstein M.J., Mitchell E.P. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005, 23(4):338-351.
29. Hara M., Kanemitsu Y., Hirai T., Komori K., Kato T. Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Dis. Colon Rectum 2008, 51(11):1675-1680.
30. San Jose M.E., Alvarez D., Valdes L., et al. Utility of tumor markers in the diagnosis of neoplastic pleural effusion. J. Clin. Chim. Acta 1997, 265:193-205.
31. Paganuzzi M., Onetto M., Marroni P., Filiberti R., Tassara E., Parodi S., et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001, 119:1138-1142.
32. Coppola D., Szabo M., Boulware D., et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 2004, 10:184-190.
33. Schneider S., Yochim J., Brabender J., et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin. Cancer Res. 2004, 10:1588-1596.
34. Pass H.I., Lott D., Lonardo F., et al. Asbestos exposure, pleural mesothelioma and serum osteopontin levels. N. Eng. J. Med. 2005, 353:1564-1573.
35. Park E.K., Thomas P.S., Johnson A.R., Yates D.H. Osteopontin levels in an asbestos-exposed population. Clin. Cancer Res. 2009, 15:1362-1366.
36. Grigoriu B.D., Scherpereel A., Devos P., et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 2007, 13:2928-2935.
37. Creaney J., Yeoman D., Demelker Y., et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J. Thorac. Oncol. 2008, 3:851-857.
38. Park E.K., Thomas P.S., Johnson A.R., et al. Osteopontin levels in a asbestos-exposed population. Clin. Cancer Res. 2009, 15:1362-1366.
39. Cristaudo A., Foddis R., Bonotti A., et al. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int. J. Biol. Markers 2010, 25(3):164-170.
40. O'Regan A.W. Asbestos exposure and osteopontin. N. Engl. J. Med. 1996, 354:304-305.
41. Ho M., Onda M., Wang Q.C., et al. Mesothelin is shed from tumor cells. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1751.
42. Chang K., Pai I.H., Pass H., Pogrebniak H.W., Tsao M.S., Pastan I., et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am. J. Surg. Pathol. 1991, 16:259-268.
43. Ordoñez N.G. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod. Pathol. 2003, 16(3):192-197.
44. Ordóñez N.G. Application of mesothelin immunostaining in tumor diagnosis. Am. J. Surg. Pathol. 2003, 27:1418-1428.
45. Chang K., Pai L.H., Batra J.K., Pastan I., Willingham M.C. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 1992, 52:181-186.
46. Scholler N., Fu N., Yang Y., et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. USA 1999, 96:11531-11536.
47. Hollevoet K., Bernard D., De Greeter F., et al. Glomerular filtration rate is a confounder for determination of serum soluble mesothelin. Clin. Chem. 2009, 55:1431-1433.
48. Weber D.G., Johnen G., Taeger D., et al. Assessment of confounding factors affecting the tumor markers SMRP, CA125, and CYFRA 21-1 in serum. Biomark. Insights 2010, 5:1-8.
49. Robinson B.W.S., Creaney J., Lake R., Nowak A.W., Musk A., de Klerk N., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
50. Liz Z., Verch T., Allard J.W. MESOMARK® in vitro diagnostic test for mesothelioma. Expert Opin. Med. Diagn. 2007, 1:137-142.
51. Onda M., Nagata S., Ho M., et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin. Cancer Res. 2006, 12:4225-4231.
52. Creaney J., Musk A.W., Robinson B.W. Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J. Thorac. Oncol. 2010, 5(9):1461-1466.
53. Scherpereel A., Grigoriu B., Conti M., et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 2006, 173:1155-1160.
54. Pass H.I., Wali A., Tang N., et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann. Thorac. Surg. 2008, 85:265-272.
55. Park E.K., Sandrini A., Yates D.H., et al. Soluble mesothelin-related protein in an asbestos-exposed population. The Dust Diseases Board Cohort Study. Am. J. Respir. Crit. Care Med. 2008, 178:832-837.
56. Davies H.E., Sadler R.S., Bielsa S., et al. The clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am. J. Respir. Crit. Care Med. 2009, 180(5):437-444.
57. Yamaguchi N., Hattori K., Oheda M., et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J. Biol. Chem. 1994, 269:805-808.
58. Ray M., Kindler H.L. Malignant pleural mesothelioma an update on biomarkers and treatment. Chest 2009, 136:888-896.
59. Shiomi K., Miyamoto H., Segawa T., et al. Novel ELISA system for detection of N-ERC-mesothelin in the sera of mesothelioma patients. Cancer Sci. 2006, 97:928-932.
60. Shiomi K., Hagiwara Y., Sonoue K., et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin. Cancer Res. 2008, 14:1431-1437.
61. Maeda M., Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol. Int. 2006, 56:649-654.
62. Hollevoet K., Nackaerts K., Thimpont J., et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am. J. Respir. Crit. Care Med. 2010, 181:620-625.
63. Creaney J., Yeoman D., Demlker Y., et al. Comparison of osteopontin, magakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J. Thorac. Oncol. 2008, 3:851-857.
64. Rodríguez Portal J.A., Rodríguez Becerra E., Rodríguez Rodríguez D., et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol. Biomarkers Prev. 2009, 18(2):646-650.
65. Hollevoet K., Van Cleemput J., Thimpont J., et al. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a Prospective Longitudinal Cohort Study. J. Thorac. Oncol. 2011, 6(5):889-895.
66. Roe O.D., Creaney J., Lundgren S., et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008, 61(2):235-243.
67. Creaney J., Olsen N.J., Brims F., Dick I.M., Musk A.W., et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol. Biomarkers Prev. 2010, 19(9):2238-2246.
68. Hassan R., Remaley A.T., Sampson M.L., et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 2006, 12:447-453.
69. Schneider J., Hoffmann H., Dienemann H., Herth F.J., Meister M., Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J. Thorac. Oncol. 2008, 3(11):1317-1324.
70. Wheatley-Price P., Yang B., Patsios D., Patel D., Ma C., Xu W., et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J. Oncol. 2010, 28(20):3316-3322.
71. Grigoriu B.D., Chahine B., Vachani A., Gey T., Conti M., Sterman D.H., et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am. J. Respir. Crit. Care Med. 2009, 179(10):950-954.
72. Creaney J., Yeoman D., Naumoff L.K., Hof M., Segal A., Musk A.W., et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007, 62:569-576.
73. Grigoriu B.D., Scherpereel A. Diagnostic value of soluble mesothelin in malignant mesothelioma. Thorax 2008, 63:87-88.
74. Grigoriu B.D., Scherpereel A., Devos P., Chahine B., Letourneux M., Lebailly P., et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 2007, 13:2928-2935.
75. Cristaudo A., Foddis R., Vivaldi A., Guglielmi G., Dipalma N., Filiberti R., et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin. Cancer Res. 2007, 13:5076-5081.
76. Creaney J., Francis R.J., Dick I.M., et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin. Cancer Res. 2011, 17:1181-1189.
77. Rodríguez Portal J.A., Asensio Cruz M., Arellano Orden E., et al. Mesothelin serum levels. Prognostic value in malignant pleural mesothelioma. Rev. Esp. Patol. Torac. 2010, 22(4):240-244.